Logo

Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Share this

Alnylam Reports Results of Vutrisiran in P-III HELIOS-A Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Shots:

  • The P-III HELIOS-A study evaluate vutrisiran (25mg, SC, q3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in a ratio (3:1) in 164 patients with hATTR amyloidosis with polyneuropathy at 57 sites in 22 countries
  • The trial met all 2EPs i.e., @ 18mos., therapy showed improvements in neuropathy as measured by mNIS+7, QoL, gait speed, nutritional status & overall disability compared to PBO; reduction in serum TTR levels & showed non-inferiority over  patisiran
  • The therapy showed improvements in exploratory EPs @18mos., including biomarker NT-proBNP, echocardiographic parameters & technetium uptake in a planned cohort. The therapy is currently under review by multiple regulatory authorities globally

 ­ | Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions